 |
Enrollment and recruitment remain challenging, and increased public attention to trials adds another layer of complexity that must be managed. The good news – if higher awareness is properly supported, it could bolster interest in clinical trials. However, at the same time, politicization and misinformation can set good intentions back. By understanding the resistance and being sensitive to avoiding triggers, sponsors can help sites navigate the new normal for a faster, more effective study startup. In this playbook, industry experts share their unique perspectives on evolving behaviors and what they mean for biopharma sponsors. You’ll learn:
|
